Table 6. Effect of NSAID ever-use in each exposure period (in years before the index date) on the risk of developing total prostate cancer by NSAID category.

Variable	OR (95%CI)a	P-value
Aspirin
≤1	1.00 (0.87–1.16)	0.954
1.1–6	0.93 (0.83–1.03)	0.157
6.1–11	0.96 (0.87–1.06)	0.409
11.1–16	1.02 (0.91–1.15)	0.677
16.1–21	1.10 (0.96–1.27)	0.161
21.1–26	1.00 (0.79–1.26)	0.990
Arylacetic acids
≤1	1.20 (1.06–1.37)	0.005
1.1–6	0.99 (0.91–1.08)	0.796
6.1–11	0.99 (0.90–1.09)	0.813
11.1–16	0.94 (0.84–1.05)	0.277
16.1–21	0.96 (0.83–1.12)	0.642
21.1–26	0.77 (0.57–1.05)	0.098
Butylpyrazolidines
≤1	1.35 (0.45–4.05)	0.589
1.1–6	1.25 (0.89–1.76)	0.200
6.1–11	1.13 (0.91–1.41)	0.262
11.1–16	0.79 (0.65–0.97)	0.022
16.1–21	0.99 (0.80–1.23)	0.931
21.1–26	1.05 (0.78–1.42)	0.734
Oxicams
≤1	0.90 (0.61–1.31)	0.567
1.1–6	0.96 (0.81–1.15)	0.683
6.1–11	1.01 (0.87–1.18)	0.886
11.1–16	0.96 (0.81–1.14)	0.674
16.1–21	0.84 (0.63–1.12)	0.234
Propionates
≤1	1.11 (0.96–1.30)	0.164
1.1–6	0.93 (0.85–1.01)	0.098
6.1–11	0.96 (0.88–1.05)	0.426
11.1–16	0.85 (0.76–0.94)	0.001
16.1–21	1.05 (0.92–1.20)	0.439
21.1–26	0.87 (0.68–1.12)	0.291

a) Adjusted for ever visited a urologist 1–11 years prior, SCREENED and volume of family physician visits in the 5 years prior to the index date, and to all terms listed in the table.